Welcome to our dedicated page for CARLSMED news (Ticker: CARL), a resource for investors and traders seeking the latest updates and insights on CARLSMED stock.
Carlsmed, Inc. reports developments in AI-enabled personalized spine surgery solutions for lumbar and cervical procedures. The company designs, manufactures and markets the aprevo® technology platform, which combines customized surgical planning with patient-specific implants for spine fusion procedures sold primarily to hospitals and ambulatory surgical centers.
Carlsmed news commonly covers quarterly financial results, revenue guidance, clinical data for aprevo® personalized implants, product updates for cervical and patient-specific fixation systems such as corra™, and management presentations at healthcare and medical technology investor conferences.
Carlsmed (Nasdaq: CARL), a medical technology company focused on AI-enabled personalized spine surgery solutions, has scheduled its second quarter 2025 financial results announcement for August 28, 2025, after market close.
The company will host a conference call and webcast at 1:30 PM Pacific Time on the same day. Participants are advised to register 5-10 minutes before the call begins. A replay will be available on the company's website following the event.
Carlsmed (NYSE:CARL) has secured CMS New Technology Add-On Payment (NTAP) approval for cervical fusion procedures using its aprevo® personalized interbody implants. Starting October 1, 2025, hospitals performing qualifying inpatient procedures with aprevo® devices will be eligible for up to $21,125 in additional reimbursement on top of standard Medicare payments.
The NTAP designation recognizes aprevo®'s significant clinical improvements over existing alternatives. The AI-enabled platform creates personalized implants matching each patient's unique anatomy, aiming to reduce revision surgeries. This approval follows the previous year's CMS reimbursement for Carlsmed's lumbar fusion devices. The company expects U.S. commercial launch in 2026, supported by FDA Breakthrough Device designation for cervical use.
Carlsmed (Nasdaq: CARL) has achieved a significant milestone with the first successful aprevo® cervical spine procedure performed on July 14, 2025, at UC San Diego Health. The procedure was conducted by Dr. Joseph Osorio, Chief of Spine Surgery in the Department of Neurological Surgery.
The aprevo® platform utilizes AI-powered surgical planning and digital production to create personalized spine devices that match each patient's unique anatomy and alignment requirements. The technology, which received FDA Breakthrough Device designation for cervical applications, is expected to launch commercially in the US in 2026.
Carlsmed (NASDAQ:CARL), a commercial-stage medical technology company focused on AI-enabled personalized spine surgery solutions, has announced the pricing of its initial public offering. The company is offering 6.7 million shares at $15.00 per share, with trading expected to begin on July 23, 2025, on the Nasdaq Global Select Market.
The IPO is anticipated to generate gross proceeds of approximately $100.5 million before deducting underwriting costs and other expenses. Underwriters have a 30-day option to purchase up to an additional 1,005,000 shares. BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler are serving as joint lead book-running managers, with Truist Securities and BTIG acting as joint book-runners.
Carlsmed (NASDAQ:CARL), a commercial-stage medical technology company specializing in AI-enabled personalized spine surgery solutions, has announced its initial public offering. The company plans to offer 6.7 million shares of common stock with an expected price range of $14.00 to $16.00 per share.
The underwriters will have a 30-day option to purchase up to 1,005,000 additional shares. BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler are serving as joint lead book-running managers, while Truist Securities and BTIG are acting as joint book-runners. The company has applied to list on the Nasdaq Global Select Market under the ticker symbol "CARL".